• 1
    Nickel JC. Prostatic inflammation in benign prostatic hyperplasia – the third component? Can J Urol 1994; 1: 14
  • 2
    Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84: 97681
  • 3
    Soler Soler JL, Martinez Torres JL, Hidalgo Dominguez Mdel R et al. Inflammatory changes in the obstructed prostate: the correlation between the bacteriological and histological findings. Arch Esp Urol 1999; 52: 72938
  • 4
    Nickel JC, Elhilali M, Vallancien G and the Alf-One Study Group. Prevalence, clinical significance and management of Men with BPH/LUTS and prostatitis-like symptoms. EUA presentation 2005
  • 5
    Roehrborn C and the MTOPS Research Group. The impact of acute or chronic inflammation in baseline biopsy on the risk of progression in the MTOPS study. EUA presentation 2005
  • 6
    McConnell JD, Roehrborn CG, Bautista OM et al. Medical Therapy of Prostate Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 238798
  • 7
    Araki T, Yokoyama T, Kumon H. Effectiveness of a nonsteroidal anti-inflammatory drug for nocturia on patients with benign prostatic hyperplasia: a prospective non-randomized study of loxoprofen sodium 60 mg once daily before sleeping. Acta Med Okayama 2004; 58: 459